Les Laboratoires Servier has entered into a second regional option-based deal with MacroGenics, this time to use the company’s DART™ (dual-affinity re-targeting) platform to develop and commercialise bispecific antibodies against three undisclosed cancer targets. Servier has already optioned rights to MacroGenics’ Phase I immune-stimulating monoclonal antibody MGA271. The DART alliance, which is worth US$20 M upfront to MacroGenics, is the latest step in the company’s recovery from the Phase III development failure of its type 1 diabetes drug candidate teplizumab in 2010.